IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

By afschroeder • November 23, 2025

Jiang H, Limsuwannarot S, Kulhanek KR, Pal A, Labiad O, Rysavy LW, Wong A, Su L, Cavender S, Soro J, Testa S, Ogana H, Waghray D, Tao P, Jude KM, Seet CS, Crooks GM, Moding EJ, Garcia KC, Kalbasi A. IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy. Immunity. 2025 Nov 21:S1074-7613(25)00478-9. doi: 10.1016/j.immuni.2025.10.024. Epub ahead of print. PMID: 41274289.

Tags: adoptive T cell therapy, cancer immunotherapy, CAR T cell therapy, cell signaling, common gamma chain, Cytokines, Hematology/Oncology, IL-9, IL-9R, JAK/STAT, Publications, TCR T cell therapy

Lentivirus-Based Hematopoietic Stem/Progenitor Cell Therapy Provides Effective and Long-Term Treatment in Hypophosphatasia Mouse Model

Carrillo M, Tomer S, Wang L, Cook E, Wennerberg W, Tien N, Ng H, Alagarsamy J, Rezek V, Martin H, Narisawa S, Millan JL, Crine[...]

Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival

Marsh LA, Kim TH, Zhang M, Kubalanza K, Treece CL, Chase D, Memarzadeh S, Salani R, Karlan B, Rao J, Konecny GE. Pathologic response to[...]

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH. Comparative effectiveness of CDK4/6 inhibitors[...]